Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai and Within3

Reuters Events 9 December, 2021. 10AM EST, 3PM GMT, 4PM CET. Virtual Event.
Medical affairs teams are challenged by rising costs and accelerated timelines - and hampered by inefficiency throughout the insight gathering process. These breakdowns occur before a single insight is collected: by engaging with the wrong KOLs, medical affairs won't access the right strategic insights while wasting time and effort. Add to this the deafening volume of information that HCPs are being bombarded with, and it's quickly apparent that unless you can gather and implement insights quickly, you've missed your window of opportunity to deliver value to your physicians.

But by using technology and a refined strategy to identify the right experts, engage them in the right venue and obtain key insights in real-time, teams can build a winning strategy while reducing costs and shortening timelines.

In this webinar, you'll learn:

  • How to identify and interact with the best experts for the topics your HCPs need
  • Best practices to effectively engage audiences for optimum insight volume and quality
  • First steps in advanced insight management to deliver value faster to your physicians

Register your place for this exclusive webinar here

You will hear from:

  • Harmony Garges, Chief Medical Officer, ViiV Healthcare
  • Kirk Shepard, Chief Medical Officer OBG, SVP & Head of Global Medical Affairs, Eisai
  • Lance Hill, CEO, Within3
  • Mike Abbadessa, Executive Director, Medical Affairs, Within3

Enrich your understanding on the following key topics:

  • How to identify and interact with the best experts for the topics your HCPs need
  • Best practices to effectively engage audiences for optimum insight volume and quality
  • First steps in advanced insight management to deliver value faster to your physicians
Tune in live on December 9th 10am EST / 3pm GMT / 4pm CET, to join the Q&A with the panellists

About Reuters Events

Our mission is to make pharma more open and valued.

More open so that the strongest ideas and insights are brought to the fore in a transparent, trustworthy manner. More valued by having an authentic approach to building products and services that matter to patients.

To do this, Reuters Events provides a hub for senior-level pharma executives, patient groups and other health stakeholders to exchange ideas and observe shifting trends and practices. We provide commentary, events, reports, and other expert-driven content. One of our biggest strengths is to be able to gather advice, examples and understanding on the best industry work, articulate this across multiple channels, and create a mass movement to help us all improve. This is how we will serve patients better.

We actively respond to the aims and interests of our audience, so please get in touch if you think we can do more.

Most Popular Now

Novartis signs new initial agreement with BioNTech…

Novartis announced that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding its suppo...

Roche launches comprehensive genomic profiling kit…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has launched the AVENIO Tumor Tissue CGP Kit. The Kit complements the current CGP portfolio offered by Roche and Foun...

Less talk, more action: New report sponsored by Vi…

ViiV Healthcare announced the release of Achieving health equity: a roadmap to eliminating disparities, a new report conducted by Economist Impact, a division of The Econ...

Global Heart Hub and Novartis partner to tackle AS…

Global Heart Hub and Novartis announced the launch of the Invisible Nation program. Invisible Nation will bring together a worldwide network of patient organizations and ...

Pfizer and BioNTech announce Phase 3 trial data sh…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg...

Horse hyperimmune antibody may help the fight agai…

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be a...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

New computer modelling could boost drug discovery

Scientists from Queen's University Belfast have developed a computer-aided data tool that could improve treatment for a range of illnesses. The computer modelling tool...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...

Abbott launches new initiative to drive diversity …

Abbott (NYSE: ABT) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new approaches to training, ed...

Needle-free COVID-19 vaccine shows promise

A needle-free COVID-19 vaccination could be possible, with University of Queensland scientists successfully protecting mice from the virus by administering a US-developed...